Back to search

Japan· JP-6250052F2020

エンシトレルビル フマル酸

A medicinal product containing エンシトレルビル フマル酸, registered in Japan by 塩野義製薬, on the national reimbursement list.

On Japan’s NHI price list

Checked against MHLW / PMDA (Japan) on

Informational only — not a medical device.

SOURCE REGISTER · JPMHLW / PMDA (Japan)normalisedエンシトレルビル フマル酸ATC—REGISTER NO.JP-6250052F2020PACKS LISTED0CHECKEDSeptember 25, 2026

The record

At a glance

MHLW / PMDA (Japan)
Active substance
エンシトレルビル フマル酸
Manufacturer
塩野義製薬
Country
Japan (JP)
ATC code
—
Reimbursed
Yes
Source register
MHLW / PMDA (Japan)
Last checked
September 25, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

エンシトレルビル フマル酸 in 3 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All エンシトレルビル フマル酸 products

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/2ceb2fca-b91d-43b8-b5d2-809fd5a87503
GET /v1/drugs/2ceb2fca-b91d-43b8-b5d2-809fd5a87503?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "spec": "25mg1錠",
  "marks": null,
  "source": "mhlw",
  "remarks": null,
  "yj_code": "6250052F2020",
  "category": "内用薬",
  "price_yen": 9287,
  "generic_name": "エンシトレルビル フマル酸",
  "product_name_jp": null,
  "therapeutic_class": "6250",
  "transitional_expiry": "9287"
}

See everything about エンシトレルビル フマル酸.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.